血清脂蛋白（a）与阿尔茨海默病发病风险的相关性

Abstract
Figure/Table
References (0)
Related Citation (9)

Download: PDF (992 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective： To investigate the correlation between serum lipoprotein（a）［Lp（a）］and Alzheimer′s disease（AD）.Methods： A retrospective casecontrol study was conducted on 103 AD patients>60 years old who were admitted to the Department of Neurology of Nanjing First Hospital from January 2015 to December 2018， and another 103 age and gendermatched healthy elderly subjects during the same period were selected as controls. Univariate and multivariate binary Logistic regression analysis and ROC curve were used to explore the correlation between serum Lp（a）level and the risk of AD. Furthermore， the effect of serum Lp（a） level on the risk of AD in different age groups was further investigated. Results： After the quinquepartite method of serum Lp（a） level， the first group（Q1）was used as a reference. With the increase of serum Lp（a） level， the risk of AD gradually decreased. The relative risks of groups Q2 to Q5 were 0.600， 0.471， 0.406 and 0.332（P for trend=0.011）， respectively. After adjusting for hypertension， diabetes， cardiovascular disease， serum creatinine， triglyceride， total cholesterol， highdensity lipoprotein cholesterol（HDLC）， glycosylated hemoglobin（HbA1c）， and lipoprotein associated phospholipase A2（LpPLA2）， Q1 was also used as a reference for estimating the relative risk of AD. The relative risks from Q2 to Q5 were 0.475， 0.343， 0.302 and 0.367（P for trend=0.020）， respectively. ROC curve analysis showed that the increase of serum Lp（a）level could reduce the risk of AD to a certain extent（AUC=0.601）， and it was not a good predictor. Taking lgLp（a） as the continuous variable， the increase of serum Lp（a） level was not correlated with the risk of AD in patients<75 years old（OR=1.082， P=0.769）， while the increase of serum Lp（a）level in patients≥75 years old was significantly correlated with the risk reduction of AD（OR=0.718， P=0.006）. Conclusion： There is a significant correlation between the increase of serum Lp（a）level in patients≥75 years old and the decrease of the risk of AD.

Received: 04 February 2021

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIANG Fuping1
	CHEN Nihong2
	ZHU Lin2

Cite this article:

JIANG Fuping1,CHEN Nihong2,ZHU Lin2. The correlation between serum lipoprotein（a） and risk of Alzheimer′s disease[J]. Journal of Jiangsu University(Medicine Edition), 2021, 31(05): 421-425.

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2021/V31/I05/421

［1］Moser DJ， Hoth KF， Robinson RG， et al. Blood vessel function and cognition in elderly patients with atherosclerosis［J］. Stroke， 2004， 35（11）： e369-e372.

［2］Hofman A， Ott A， Breteler MM， et al. Atherosclerosis， apolipoprotein E， and prevalence of dementia and Alzheimer′s disease in the Rotterdam Study［J］. Lancet， 1997， 349（9046）： 151-154.

［3］McGeer EG， McGeer PL. The importance of inflammatory mechanisms in Alzheimer disease［J］. Exp Gerontol， 1998， 33（5）： 371-378.

［4］Schmidt R， Schmidt H， Curb JD， et al. Early inflammation and dementia： a 25year followup of the HonoluluAsia Aging Study［J］. Ann Neurol， 2002， 52（2）： 168-174.

［5］Yankner BA. Mechanisms of neuronal degeneration in Alzheimer′s disease［J］. Neuron， 1996， 16（5）： 921-932.

［6］Kotani K， Serban MC， Penson P， et al. Evidencebased assessment of lipoprotein（a）as a risk biomarker for cardiovascular diseasessome answers and still many questions［J］. Crit Rev Clin Lab Sci， 2016， 53（6）： 370-378.

［7］Breteler MM. Vascular risk factors for Alzheimer′s disease： an epidemiologic perspective［J］. Neurobiol Aging， 2000， 21（2）： 153-160.

［8］丁彬彬，邬建民，介勇，等. 阿尔茨海默病和血管性痴呆患者血清炎症因子和生化指标的检测及临床意义［J］. 检验医学， 2016， 31（5）： 363-367.

［9］余艳. 阿尔茨海默病早期认知功能障碍与血糖、血脂及炎性因子异常的相关性研究［J］. 沈阳医学院学报， 2019， 21（3）： 204-206， 210.

［10］杨承芝，田金洲，钟剑.轻度认知损害和阿尔茨海默病患者的血脂变化［J］. 中国老年学杂志， 2007， 27（6）：545-548.

［11］Iwamoto T， Watanabe D， Umahara T， et al. Dual inverse effects of lipoprotein（a）on the dementia process in Japanese lateonset Alzheimer′s disease［J］. Psychogeriatrics， 2004， 4（3）： 64-71.

［12］Solfrizzi V， PanzaF， Introno AD， et al. Lipoprotein（a）， apolipoprotein E genotype， and risk of Alzheimer′s disease［J］. J Neurol Neurosurg Psychiatry， 2002， 72（6）： 732-736.

［13］Mooser V， Helbecque N， Miklossy J， et al. Interactions between apolipoprotein E and apolipoprotein（a）in patients with lateonset Alzheimer disease［J］. Ann Intern Med， 2000， 132（7）： 533-537.

［14］Kunutsor SK， Khan H， Nyyssnen K， et al. Is lipoprotein（a）protective of dementia?［J］. Eur J Epidemiol， 2016， 31（11）： 1149-1152.

［15］Pokharel Y， Mouhanna F， Nambi V， et al. ApoB， smalldense LDLC， Lp（a）， LpPLA2 activity， and cognitive change［J］. Neurology， 2019， 92（22）： e2580-e2593.

［16］Sarti C， Pantoni L， Pracucci G， et al. Lipoprotein（a）and cognitive performances in an elderly white population： Crosssectional and followup data［J］. Stroke， 2001， 32（7）： 1678-1683.

［17］Wardlaw JM， Smith C， Dichgans M. Small vessel disease： mechanisms and clinical implications［J］. Lancet Neurol， 2019，18（7）： 684-696.

［18］Montagne A， Nation DA， Sagare AP， et al. APOE4 leads to bloodbrain barrier dysfunction predicting cognitive decline［J］. Nature， 2020， 581（7806）： 71-76.

［19］Pepe G， Chimienti G， Liuzzi GM， et al. Lipoprotein（a） in the cerebrospinal fluid of neurological patients with bloodcerebrospinal fluid barrier dysfunction［J］. Clin Chem， 2006， 52（11）： 2043-2048.

［20］Yamazaki Y， Zhao N， Caulfield TR， et al. Apolipoprotein E and Alzheimer disease： pathobiology and targeting strategies［J］. Nat Rev Neurol， 2019， 15（9）： 501-518.

［21］Mosconi L， Perani D， Sorbi S， et al. MCI conversion to dementia and the APOE genotype： a prediction study with FDGPET［J］. Neurology， 2004，63（12）： 2332-2340.